Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Cardiff Oncology (CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has granted stock options as an employment inducement. The company issued non-qualified stock options for 35,040 shares to one new employee on April 14, 2025.
The options were granted under Nasdaq Listing Rule 5635(c)(4) with an exercise price of $2.79 per share, matching Cardiff's closing stock price on April 14, 2025. The vesting schedule spans 4 years, with 25% vesting after the first year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Cardiff Oncology (CRDF) has completed patient enrollment in its Phase 2 CRDF-004 trial, evaluating onvansertib combined with standard of care for first-line RAS-mutated metastatic colorectal cancer (mCRC) treatment. The trial, conducted across 41 U.S. clinical sites, involves patients with documented KRAS or NRAS mutations and unresectable disease.
The study design includes three arms where patients receive either 20mg onvansertib plus standard of care (FOLFIRI/FOLFOX with bevacizumab), 30mg onvansertib plus standard of care, or standard of care alone. The trial's primary endpoint is objective response rate (ORR), with secondary endpoints including progression-free survival, duration of response, and safety.
Initial results were released in December 2024, with additional clinical data expected in the first half of 2025.
Cardiff Oncology reported significant progress in its first-line RAS-mutated metastatic colorectal cancer (mCRC) clinical trial, with patients receiving 30mg onvansertib showing a 64% response rate compared to 33% in the control arm. The company successfully completed a $40 million oversubscribed offering and secured a new patent for onvansertib treatment in KRAS-mutated mCRC.
The company's financial position remains strong with $91.7 million in cash and equivalents as of December 31, 2024, providing runway into Q1 2027. Operating expenses increased to $49.3 million for 2024, up from $45.9 million in 2023, primarily due to clinical program costs and higher staffing expenses.
Additional clinical updates from the CRDF-004 trial are expected in H1 2025. The company also presented promising data at the San Antonio Breast Cancer Symposium and published clinical results in the Journal of Clinical Oncology.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has announced its participation in two upcoming investor conferences.
At the B. Riley Securities Precision Oncology & Radiopharma Conference on February 28, 2025, CEO Mark Erlander will participate in a panel discussion focusing on improving responses in colorectal cancer. This event will be held in New York City and is exclusively for in-person attendees.
Additionally, the company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 11:50 AM ET. This presentation will be accessible via webcast through Cardiff Oncology's website in the 'Events' section, with a replay available after the presentation.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focused on PLK1 inhibition for cancer therapies, has announced it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT following market close.
Interested parties can access the webcast through the 'Investors' section of Cardiff Oncology's website. A replay of the call will be made available in the investor relations section afterward.
Cardiff Oncology (Nasdaq: CRDF) has announced the pricing of an oversubscribed underwritten registered direct offering of 15,384,619 common stock shares at $2.60 per share, aiming to raise approximately $40 million in gross proceeds. The offering attracted new mutual fund and healthcare dedicated investors, alongside existing investors' support.
The company plans to use the net proceeds to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) and for working capital. TD Cowen is leading the offering as book-runner, with William Blair, H.C. Wainwright & Co., and Craig-Hallum also participating in various roles. The offering is expected to close around December 11, 2024.
Cardiff Oncology (NASDAQ: CRDF) announced positive initial data from its Phase 2 CRDF-004 trial evaluating onvansertib combined with standard-of-care (SoC) in first-line RAS-mutated metastatic colorectal cancer patients. The trial demonstrated a 64% objective response rate (ORR) in the 30mg onvansertib dose arm versus 33% ORR in the control arm.
The 30mg dose showed superior results compared to the 20mg dose (64% vs. 50% ORR) with deeper tumor regression. The drug was well-tolerated at both doses. The randomized trial enrolled patients with KRAS or NRAS mutations, combining onvansertib with FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Additional clinical data is expected in 1H 2025.
Cardiff Oncology (Nasdaq: CRDF) has been granted U.S. patent No. 12,144,813 by the USPTO, protecting the use of onvansertib in combination with bevacizumab for treating KRAS mutated metastatic colorectal cancer (mCRC) patients who haven't previously received bevacizumab treatment. The patent extends protection through 2043. Onvansertib, a PLK1 inhibitor, is currently being evaluated in a Phase 2 randomized trial (CRDF-004) in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for first-line treatment of RAS-mutated mCRC patients. Initial data is expected by end of 2024.
Cardiff Oncology (CRDF) reported Q3 2024 results highlighting positive Phase 2 trial results of onvansertib combined with FOLFIRI and bev in second-line KRAS mutant mCRC. The trial showed a 7.7x greater clinical benefit in bev naïve patients. The company expects an initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial by end of 2024. Financial highlights include $57.7 million in cash and equivalents, with quarterly cash burn of $10.5 million. Operating expenses increased to $12.8 million, up $1.8 million year-over-year. Current cash runway extends into Q1 2026.
Cardiff Oncology announced the publication of Phase 2 trial data in the Journal of Clinical Oncology, evaluating onvansertib combined with FOLFIRI and bevacizumab for second-line treatment of KRAS mutant metastatic colorectal cancer (mCRC). The study showed significant results, particularly in bevacizumab-naïve patients, demonstrating a 77% objective response rate compared to 10% in bevacizumab-exposed patients. The treatment combination showed a median progression-free survival of 14.9 months in bevacizumab-naïve patients versus 6.6 months in bevacizumab-exposed patients. Based on these findings, the company has initiated CRDF-004, a Phase 2 randomized trial for first-line treatment, with initial data expected in H2 2024.